UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2023
COMMISSION FILE NUMBER 001-38455
MorphoSys AG
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On August 09, 2023, MorphoSys AG (the “Company”) issued a press release with the Q2/H1 2023 financial results attached hereto as Exhibit 99.1. On August 10, 2023, MorphoSys AG, held its Q2/H1 2023 results conference call attached hereto as Exhibit 99.2.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MORPHOSYS AG (Registrant)
Date: August 10, 2023 By: /s/ i.A Isabelle Degbegni
Name: Isabelle Degbegni
Title: Director Investor Relation
By: /s/ i.A. Dr. Robert Mayer
Name: Dr. Robert Mayer
Title: Director Investor Relations
